Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force-Reference-Cited by-同舟云学术

Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force

Published:2023-04 Issue:4 Volume:26 Page:449-460
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Tervonen Tommi,Veldwijk Jorien,Payne Katherine,Ng Xinyi,Levitan Bennett,Lackey Leila G.,Marsh Kevin,Thokala Praveen,Pignatti Francesco,Donnelly Anne,Ho Martin

Funder

Novartis

Universiteit Utrecht

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference80 articles.

1. Criteria and process for initiating and developing an ISPOR Good Practices Task Force report;Malone;Value Health,2020

2. Incorporating patient-preference evidence into regulatory decision making;Ho;Surg Endosc,2015

3. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism;Beyer-Westendorf;Thromb Haemost,2015

4. Structured frameworks to increase the transparency of the assessment of benefits and risks of medicines: current status and possible future directions;Pignatti;Clin Pharmacol Ther,2015

5. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies;Ho;Value Health,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices;Value in Health;2024-09

2. Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding;The Patient - Patient-Centered Outcomes Research;2024-08-28

3. Methodologies for the benefit-risk analysis of medical devices: A systematic review;2024-08-05

4. Key Opinion Leaders’ Interviews to Inform the Future of Benefit–Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations;Drug Safety;2024-06-01

5. Methodological guidelines and publications of benefit–risk assessment for health technology assessment: a scoping review;BMJ Open;2024-06